Literature DB >> 26187374

Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice.

Angélica Pupin Schiavon1, Jéssica Mendes Bonato1, Humberto Milani1, Francisco Silveira Guimarães2, Rúbia Maria Weffort de Oliveira3.   

Abstract

Therapeutic effects of antidepressants and atypical antipsychotics may arise partially from their ability to stimulate neurogenesis. Cannabidiol (CBD), a phytocannabinoid present in Cannabis sativa, presents anxiolytic- and antipsychotic-like effects in preclinical and clinical settings. Anxiolytic-like effects of repeated CBD were shown in chronically stressed animals and these effects were parallel with increased hippocampal neurogenesis. However, antidepressant-like effects of repeated CBD administration in non-stressed animals have been scarcely reported. Here we investigated the behavioral consequences of single or repeated CBD administration in non-stressed animals. We also determined the effects of CBD on cell proliferation and neurogenesis in the dentate gyrus (DG) and subventricular zone (SVZ). Single CBD 3mg/kg administration resulted in anxiolytic-like effect in mice submitted to the elevated plus maze (EPM). In the tail suspension test (TST), single or repeated CBD administration reduced immobility time, an effect that was comparable to those of imipramine (20 mg/kg). Moreover, repeated CBD administration at a lower dose (3 mg/kg) increased cell proliferation and neurogenesis, as seen by an increased number of Ki-67-, BrdU- and doublecortin (DCX)-positive cells in both in DG and SVZ. Despite its antidepressant-like effects in the TST, repeated CBD administration at a higher dose (30 mg/kg) decreased cell proliferation and neurogenesis in the hippocampal DG and SVZ. Our findings show a dissociation between behavioral and proliferative effects of repeated CBD and suggest that the antidepressant-like effects of CBD may occur independently of adult neurogenesis in non-stressed Swiss mice.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant; Cannabidiol; Neurogenesis; Subgranular zone; Subventricular zone; Swiss mice

Mesh:

Substances:

Year:  2015        PMID: 26187374     DOI: 10.1016/j.pnpbp.2015.06.017

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  34 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

3.  Cannabis-related hippocampal volumetric abnormalities specific to subregions in dependent users.

Authors:  Yann Chye; Chao Suo; Murat Yücel; Lauren den Ouden; Nadia Solowij; Valentina Lorenzetti
Journal:  Psychopharmacology (Berl)       Date:  2017-04-19       Impact factor: 4.530

4.  Amygdala-hippocampal innervation modulates stress-induced depressive-like behaviors through AMPA receptors.

Authors:  Hui Ma; Chenyang Li; Jinpeng Wang; Xiaochen Zhang; Mingyue Li; Rong Zhang; Zhuo Huang; Yong Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

5.  Subacute cannabidiol alters genome-wide DNA methylation in adult mouse hippocampus.

Authors:  Nicole M Wanner; Mathia Colwell; Chelsea Drown; Christopher Faulk
Journal:  Environ Mol Mutagen       Date:  2020-08-10       Impact factor: 3.216

6.  Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.

Authors:  Yane Costa Chaves; Karina Genaro; José Alexandre Crippa; Joice Maria da Cunha; Janaína Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2021-01-19       Impact factor: 3.584

Review 7.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

8.  Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure.

Authors:  Mahshid Hosseinzadeh; Sara Nikseresht; Fariba Khodagholi; Nima Naderi; Nader Maghsoudi
Journal:  J Mol Neurosci       Date:  2016-01-06       Impact factor: 3.444

9.  Acute and long-term effects of Δ9-tetrahydrocannabinol on object recognition and anxiety-like activity are age- and strain-dependent in mice.

Authors:  C R Kasten; Y Zhang; S L Boehm
Journal:  Pharmacol Biochem Behav       Date:  2017-10-28       Impact factor: 3.533

10.  Cannabidiol does not display drug abuse potential in mice behavior.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Juan Medrano-Relinque; Carmen M Navarrón; Francisco Navarrete; Jorge Manzanares
Journal:  Acta Pharmacol Sin       Date:  2018-07-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.